Free Newsletter
Drugmakers cut deals in price-inflation suit
Remember the legal wrangle over the price of cancer drugs? The lawsuit pitted insurers, patients, attorneys general--perhaps even a few kitchen sinks--against 30 drug companies, including GlaxoSmithKline, Bristol-Myers Squibb, AstraZeneca, Schering Plough. At issue: Whether the companies artificially inflated drug prices, then sold the drugs to doctors at a discount, giving doctors the spread--and themselves an unfair advantage over competitors who weren't playing the game (though with so many companies allegedly involved, who wasn't?).
The latest? GlaxoSmithKline settled for $70 million, and Bristol-Myers and AstraZeneca are cutting deals. In June, a judge found Bristol-Myers, AstraZeneca and Schering-Plough liable for the price inflation. No word yet on whether Schering-Plough is also negotiating a settlement.
- read this item from The Wall Street Journal
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: